[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f8zfO7c4kuOn3IzfRFYoSKA8psuiu-Fz54mZ_iAvc0oE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Poitiers University Hospital",[4],309,false,63,19,176695,21,235,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Chronic Myeloid Leukemia",8,{"name":18,"count":19},"Acute Respiratory Failure",7,{"name":21,"count":22},"Failed Back Surgery Syndrome",5,{"name":24,"count":25},"Breast Cancer",4,{"name":27,"count":25},"Alzheimer Disease",{"name":29,"count":25},"Pain",{"name":31,"count":25},"Sleep Quality",{"name":33,"count":34},"Healthy Volunteers",3,[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04751877","Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With\u002FWithout Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; \u003C 80 Years).","2024-06-18","Isatuximab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06646978","Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial","2025-05","Imatinib",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT07445347","Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network","2026-06","Bevacizumab",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06278519","CARdiAc Mri and BiOLogical samplEs at the Acute Phase of a Myocardial Infarction (CARAMBOLE)","2026-08-01","Blood, urinary and feces collection",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06846034","Effect of Acute Hypoxia on Renal Hemodynamic in Healthy Volunteers, Patients With Diabetes and Patients With Diabetes and Kidney Disease","2026-09","Renal clairance study",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05275881","Impact of Virtual Reality in Hematology and Oncology During Invasive Procedures in Children, Adolescents and Young Adults, from 7 to Less Than 25 Years Old","2026-11-13","Usual Practices",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05790707","EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment","2027-01","Antiarrhythmic drug",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT03656081","Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole","2027-06","inhaled Ambisome®",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT05589220","Study to Evaluate Music Therapy and Nicotine Replacement Therapy on Craving Related to Smoking Cessation in Students","2028-01","Nicotine replacement",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT07236177","B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.","2028-02-03","blood plasma sample",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,126,144,170,213,243,265,289,307,325,351,369,397,415,448,470,498,523,548,572,592,613,639,666,684,710,728,753,779,797,822,846,884,910,950,977,1005,1023,1041,1059,1085,1111,1129,1147,1165,1190,1208,1233,1261,1279,1297,1327,1345,1363,1381,1399,1426,1450,1476,1494,1520,1545,1570,1588,1613,1638,1663,1689,1707,1725,1751,1769,1794,1812,1830,1856,1874,1892,1915,1939,1965,1983,2001,2026,2048,2072,2090,2114,2139,2164,2189,2213,2231,2253,2278,2296,2314,2332,2356,2382,2409,2434,2460,2478,2501,2519,2544,2573,2591,2617,2643],{"intervention":95,"totalTrials":96,"cells":97},"Prevenar 13 + Pneumovax 23",1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":124},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":114},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":122},"NCT04460235","Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma","RECRUITING",[91],"2028-06","2029-06","2021-09-07",160,[119,120,121],"Vaccine","Streptococcus Pneumoniae","Lymphoma, Non-Hodgkin",[95,123],"PREVENAR20",{"trials":125,"activeCount":100},[],{"intervention":123,"totalTrials":96,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":136,"NA":142},{"trials":129,"activeCount":100},[],{"trials":131,"activeCount":100},[],{"trials":133,"activeCount":100},[],{"trials":135,"activeCount":100},[],{"trials":137,"activeCount":96,"soonestReadout":114},[138],{"nctId":110,"briefTitle":111,"status":112,"phases":139,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":140,"interventions":141},[91],[119,120,121],[95,123],{"trials":143,"activeCount":100},[],{"intervention":145,"totalTrials":96,"cells":146},"Blood samples for PK",{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":168},{"trials":148,"activeCount":100},[],{"trials":150,"activeCount":100},[],{"trials":152,"activeCount":100},[],{"trials":154,"activeCount":100},[],{"trials":156,"activeCount":96,"soonestReadout":162},[157],{"nctId":158,"briefTitle":159,"status":160,"phases":161,"primaryCompletion":162,"completion":162,"start":163,"enrollment":12,"conditions":164,"interventions":167},"NCT07490509","Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer","NOT_YET_RECRUITING",[91],"2029-04","2026-04",[165,166,24],"Abemaciclib","Abemaciclib-related Diarrhea",[145],{"trials":169,"activeCount":100},[],{"intervention":40,"totalTrials":171,"cells":172},2,{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":195,"PHASE4":209,"NA":211},{"trials":174,"activeCount":100},[],{"trials":176,"activeCount":100},[],{"trials":178,"activeCount":100},[179],{"nctId":180,"briefTitle":181,"status":182,"phases":183,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":191},"NCT04287855","Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma","UNKNOWN",[89],"2025-04-15","2026-04-15","2020-08-28",82,[189,190],"Multiple Myeloma in Relapse","Multiple Myeloma, Refractory",[40,192,193,194],"Carfilzomib","Pomalidomide","Dexamethasone",{"trials":196,"activeCount":96,"soonestReadout":39},[197],{"nctId":37,"briefTitle":38,"status":198,"phases":199,"primaryCompletion":39,"completion":200,"start":201,"enrollment":202,"conditions":203,"interventions":206},"ACTIVE_NOT_RECRUITING",[90],"2027-08-17","2021-07-17",270,[204,205],"Multiple Myeloma","Myeloma",[40,207,208,194],"Lenalidomide","Bortezomib",{"trials":210,"activeCount":100},[],{"trials":212,"activeCount":100},[],{"intervention":207,"totalTrials":171,"cells":214},{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":233,"PHASE4":239,"NA":241},{"trials":216,"activeCount":100},[],{"trials":218,"activeCount":100},[],{"trials":220,"activeCount":100},[221],{"nctId":222,"briefTitle":223,"status":224,"phases":225,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},"NCT00779922","Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function","COMPLETED",[89],"2012-09","2008-11",39,[204,230],"Impaired Renal Function",[232],"lenalidomide",{"trials":234,"activeCount":96,"soonestReadout":39},[235],{"nctId":37,"briefTitle":38,"status":198,"phases":236,"primaryCompletion":39,"completion":200,"start":201,"enrollment":202,"conditions":237,"interventions":238},[90],[204,205],[40,207,208,194],{"trials":240,"activeCount":100},[],{"trials":242,"activeCount":100},[],{"intervention":194,"totalTrials":171,"cells":244},{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":255,"PHASE4":261,"NA":263},{"trials":246,"activeCount":100},[],{"trials":248,"activeCount":100},[],{"trials":250,"activeCount":100},[251],{"nctId":180,"briefTitle":181,"status":182,"phases":252,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":253,"interventions":254},[89],[189,190],[40,192,193,194],{"trials":256,"activeCount":96,"soonestReadout":39},[257],{"nctId":37,"briefTitle":38,"status":198,"phases":258,"primaryCompletion":39,"completion":200,"start":201,"enrollment":202,"conditions":259,"interventions":260},[90],[204,205],[40,207,208,194],{"trials":262,"activeCount":100},[],{"trials":264,"activeCount":100},[],{"intervention":75,"totalTrials":96,"cells":266},{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":285,"NA":287},{"trials":268,"activeCount":100},[],{"trials":270,"activeCount":100},[],{"trials":272,"activeCount":100},[],{"trials":274,"activeCount":96,"soonestReadout":74},[275],{"nctId":72,"briefTitle":73,"status":112,"phases":276,"primaryCompletion":74,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":282},[90],"2029-12","2018-12-19",224,[281],"Chronic Pulmonary Aspergillosis",[75,283,284],"inhaled placebo","Itraconazole",{"trials":286,"activeCount":100},[],{"trials":288,"activeCount":100},[],{"intervention":283,"totalTrials":96,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":303,"NA":305},{"trials":292,"activeCount":100},[],{"trials":294,"activeCount":100},[],{"trials":296,"activeCount":100},[],{"trials":298,"activeCount":96,"soonestReadout":74},[299],{"nctId":72,"briefTitle":73,"status":112,"phases":300,"primaryCompletion":74,"completion":277,"start":278,"enrollment":279,"conditions":301,"interventions":302},[90],[281],[75,283,284],{"trials":304,"activeCount":100},[],{"trials":306,"activeCount":100},[],{"intervention":284,"totalTrials":96,"cells":308},{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":321,"NA":323},{"trials":310,"activeCount":100},[],{"trials":312,"activeCount":100},[],{"trials":314,"activeCount":100},[],{"trials":316,"activeCount":96,"soonestReadout":74},[317],{"nctId":72,"briefTitle":73,"status":112,"phases":318,"primaryCompletion":74,"completion":277,"start":278,"enrollment":279,"conditions":319,"interventions":320},[90],[281],[75,283,284],{"trials":322,"activeCount":100},[],{"trials":324,"activeCount":100},[],{"intervention":326,"totalTrials":96,"cells":327},"treatment of TKI in CML",{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":347,"NA":349},{"trials":329,"activeCount":100},[],{"trials":331,"activeCount":100},[],{"trials":333,"activeCount":100},[],{"trials":335,"activeCount":96,"soonestReadout":340},[336],{"nctId":337,"briefTitle":338,"status":198,"phases":339,"primaryCompletion":340,"completion":341,"start":342,"enrollment":343,"conditions":344,"interventions":346},"NCT05753384","Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System",[90],"2028-12-01","2029-12-01","2023-12-01",170,[345,15],"Tyrosine Kinase Inhibitors",[326],{"trials":348,"activeCount":100},[],{"trials":350,"activeCount":100},[],{"intervention":208,"totalTrials":96,"cells":352},{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":359,"PHASE4":365,"NA":367},{"trials":354,"activeCount":100},[],{"trials":356,"activeCount":100},[],{"trials":358,"activeCount":100},[],{"trials":360,"activeCount":96,"soonestReadout":39},[361],{"nctId":37,"briefTitle":38,"status":198,"phases":362,"primaryCompletion":39,"completion":200,"start":201,"enrollment":202,"conditions":363,"interventions":364},[90],[204,205],[40,207,208,194],{"trials":366,"activeCount":100},[],{"trials":368,"activeCount":100},[],{"intervention":85,"totalTrials":96,"cells":370},{"EARLY_PHASE1":371,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":393,"NA":395},{"trials":372,"activeCount":96,"soonestReadout":84},[373],{"nctId":82,"briefTitle":83,"status":112,"phases":374,"primaryCompletion":84,"completion":375,"start":376,"enrollment":377,"conditions":378,"interventions":385},[87],"2028-03-03","2026-02-03",220,[24,379,380,381,382,383,384],"Pancreatic Cancer","Pulmonary Cancer","Volatile Organic Compound","Glycosidase Activity","Probes","Tumor Markers, Biological",[85,386],"blood sampling",{"trials":388,"activeCount":100},[],{"trials":390,"activeCount":100},[],{"trials":392,"activeCount":100},[],{"trials":394,"activeCount":100},[],{"trials":396,"activeCount":100},[],{"intervention":386,"totalTrials":96,"cells":398},{"EARLY_PHASE1":399,"PHASE1":405,"PHASE2":407,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":400,"activeCount":96,"soonestReadout":84},[401],{"nctId":82,"briefTitle":83,"status":112,"phases":402,"primaryCompletion":84,"completion":375,"start":376,"enrollment":377,"conditions":403,"interventions":404},[87],[24,379,380,381,382,383,384],[85,386],{"trials":406,"activeCount":100},[],{"trials":408,"activeCount":100},[],{"trials":410,"activeCount":100},[],{"trials":412,"activeCount":100},[],{"trials":414,"activeCount":100},[],{"intervention":80,"totalTrials":171,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":425,"NA":427},{"trials":418,"activeCount":100},[],{"trials":420,"activeCount":100},[],{"trials":422,"activeCount":100},[],{"trials":424,"activeCount":100},[],{"trials":426,"activeCount":100},[],{"trials":428,"activeCount":96,"soonestReadout":79},[429,441],{"nctId":430,"briefTitle":431,"status":182,"phases":432,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":439},"NCT06130423","Study to Evaluate Music Therapy and Nicotine Replacement Therapy on Craving Related to Smoking Cessation in Health Staff",[92],"2025-01-10","2026-01-10","2024-02-28",50,[438],"Smoking Cessation",[440,80],"Music intervention",{"nctId":77,"briefTitle":78,"status":112,"phases":442,"primaryCompletion":79,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":447},[92],"2028-03","2022-12-13",120,[438],[80],{"intervention":70,"totalTrials":96,"cells":449},{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":451,"activeCount":100},[],{"trials":453,"activeCount":100},[],{"trials":455,"activeCount":100},[],{"trials":457,"activeCount":100},[],{"trials":459,"activeCount":100},[],{"trials":461,"activeCount":96,"soonestReadout":69},[462],{"nctId":67,"briefTitle":68,"status":112,"phases":463,"primaryCompletion":69,"completion":464,"start":465,"enrollment":445,"conditions":466,"interventions":469},[92],"2027-07","2023-04-21",[467,468],"Mild Cognitive Impairment","Persistent Atrial Fibrillation",[70],{"intervention":471,"totalTrials":96,"cells":472},"Nicotine Replacement Therapy",{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":479,"PHASE4":481,"NA":483},{"trials":474,"activeCount":100},[],{"trials":476,"activeCount":100},[],{"trials":478,"activeCount":100},[],{"trials":480,"activeCount":100},[],{"trials":482,"activeCount":100},[],{"trials":484,"activeCount":96,"soonestReadout":489},[485],{"nctId":486,"briefTitle":487,"status":160,"phases":488,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":497},"NCT07412717","The Efficacy of Combining Music Intervention With Nicotine Replacement Therapy to Reduce Smoking Craving, Among Healthcare Professionals Who Are Trying to Quit.",[92],"2029-03-01","2030-02-01","2026-03-01",80,[471,494,495,496],"Healthcare Professionals","Tobacco Craving","Tabacco Cessation",[471],{"intervention":60,"totalTrials":96,"cells":499},{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":501,"activeCount":100},[],{"trials":503,"activeCount":100},[],{"trials":505,"activeCount":100},[],{"trials":507,"activeCount":100},[],{"trials":509,"activeCount":100},[],{"trials":511,"activeCount":96,"soonestReadout":59},[512],{"nctId":57,"briefTitle":58,"status":112,"phases":513,"primaryCompletion":59,"completion":59,"start":514,"enrollment":515,"conditions":516,"interventions":522},[92],"2025-02-13",30,[517,518,519,520,521],"Diabetes","Diabetic Kidney Disease","Hypoxia","Healthy Volunteer","Diabetic Nephropathies",[60],{"intervention":65,"totalTrials":96,"cells":524},{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":531,"PHASE4":533,"NA":535},{"trials":526,"activeCount":100},[],{"trials":528,"activeCount":100},[],{"trials":530,"activeCount":100},[],{"trials":532,"activeCount":100},[],{"trials":534,"activeCount":100},[],{"trials":536,"activeCount":96,"soonestReadout":64},[537],{"nctId":62,"briefTitle":63,"status":112,"phases":538,"primaryCompletion":64,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":547},[92],"2026-12-13","2022-10-13",60,[543,544,545,29,546],"Virtual Reality","Pediatrics","Cancer","Procedural Pain",[65],{"intervention":50,"totalTrials":96,"cells":549},{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":558,"NA":560},{"trials":551,"activeCount":100},[],{"trials":553,"activeCount":100},[],{"trials":555,"activeCount":100},[],{"trials":557,"activeCount":100},[],{"trials":559,"activeCount":100},[],{"trials":561,"activeCount":96,"soonestReadout":49},[562],{"nctId":47,"briefTitle":48,"status":563,"phases":564,"primaryCompletion":49,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":571},"ENROLLING_BY_INVITATION",[],"2026-11","2025-10-15",111,[569,570,50],"Hereditary Hemorrhagic Telangiectasia (HHT)","Pulmonary Hypertension",[50],{"intervention":55,"totalTrials":96,"cells":573},{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":582,"NA":584},{"trials":575,"activeCount":100},[],{"trials":577,"activeCount":100},[],{"trials":579,"activeCount":100},[],{"trials":581,"activeCount":100},[],{"trials":583,"activeCount":100},[],{"trials":585,"activeCount":96,"soonestReadout":54},[586],{"nctId":52,"briefTitle":53,"status":198,"phases":587,"primaryCompletion":54,"completion":54,"start":588,"enrollment":343,"conditions":589,"interventions":591},[92],"2024-03-01",[590],"Myocardial Infarction",[55],{"intervention":45,"totalTrials":96,"cells":593},{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":595,"activeCount":100},[],{"trials":597,"activeCount":100},[],{"trials":599,"activeCount":100},[],{"trials":601,"activeCount":100},[],{"trials":603,"activeCount":100},[],{"trials":605,"activeCount":96,"soonestReadout":44},[606],{"nctId":42,"briefTitle":43,"status":563,"phases":607,"primaryCompletion":44,"completion":44,"start":608,"enrollment":609,"conditions":610,"interventions":612},[],"2024-05-01",787,[611],"Chronic Myeloid Leukemia (CML)",[45],{"intervention":614,"totalTrials":96,"cells":615},"cefoxitin",{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":624,"NA":637},{"trials":617,"activeCount":100},[],{"trials":619,"activeCount":100},[],{"trials":621,"activeCount":100},[],{"trials":623,"activeCount":100},[],{"trials":625,"activeCount":100},[626],{"nctId":627,"briefTitle":628,"status":224,"phases":629,"primaryCompletion":630,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":636},"NCT02703857","Study of Repeated Cefoxitin Administration in Major Abdominal Surgery Using a Microdialysis Technique",[91],"2016-09-15","2016-09-20","2016-02",12,[635],"Antibiotic Prophylaxis Surgery",[614],{"trials":638,"activeCount":100},[],{"intervention":640,"totalTrials":96,"cells":641},"Povidone-Iodine-Alcohol",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":664},{"trials":643,"activeCount":100},[],{"trials":645,"activeCount":100},[],{"trials":647,"activeCount":100},[],{"trials":649,"activeCount":100},[],{"trials":651,"activeCount":100},[652],{"nctId":653,"briefTitle":654,"status":224,"phases":655,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":662},"NCT03757143","Chlorhexidine-Alcohol Versus Povidone Iodine-Alcohol, Combined or Not With Use of a Bundle of New Devices, for Prevention of Intravascular-catheter Colonization and Catheter Failure",[91],"2019-09-27","2019-01-07",1000,[660,661],"Intravascular-catheter Colonization","Catheter Failure",[640,663],"Chlorhexidine-Alcohol",{"trials":665,"activeCount":100},[],{"intervention":663,"totalTrials":96,"cells":667},{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":676,"NA":682},{"trials":669,"activeCount":100},[],{"trials":671,"activeCount":100},[],{"trials":673,"activeCount":100},[],{"trials":675,"activeCount":100},[],{"trials":677,"activeCount":100},[678],{"nctId":653,"briefTitle":654,"status":224,"phases":679,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":680,"interventions":681},[91],[660,661],[640,663],{"trials":683,"activeCount":100},[],{"intervention":685,"totalTrials":96,"cells":686},"0.5% sodium hypochlorite solution",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":695,"NA":708},{"trials":688,"activeCount":100},[],{"trials":690,"activeCount":100},[],{"trials":692,"activeCount":100},[],{"trials":694,"activeCount":100},[],{"trials":696,"activeCount":100},[697],{"nctId":698,"briefTitle":699,"status":224,"phases":700,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":706},"NCT04391660","Estimation of the Incidence of Colonization of Peripheral Venous Catheters After Skin Disinfection With 0.5% Sodium Hypochlorite, Preceded or Not by an Application of 70% Ethanol",[91],"2021-01-08","2020-06-15",240,[705],"Skin Disinfection Before Peripheral Venous Catheter Insertion",[685,707],"0.5% sodium hypochlorite solution and 70% ethanol",{"trials":709,"activeCount":100},[],{"intervention":707,"totalTrials":96,"cells":711},{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":720,"NA":726},{"trials":713,"activeCount":100},[],{"trials":715,"activeCount":100},[],{"trials":717,"activeCount":100},[],{"trials":719,"activeCount":100},[],{"trials":721,"activeCount":100},[722],{"nctId":698,"briefTitle":699,"status":224,"phases":723,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":724,"interventions":725},[91],[705],[685,707],{"trials":727,"activeCount":100},[],{"intervention":729,"totalTrials":96,"cells":730},"Skin disinfection",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":739,"NA":751},{"trials":732,"activeCount":100},[],{"trials":734,"activeCount":100},[],{"trials":736,"activeCount":100},[],{"trials":738,"activeCount":100},[],{"trials":740,"activeCount":100},[741],{"nctId":742,"briefTitle":743,"status":224,"phases":744,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":750},"NCT00259350","Chlorhexidine vs Povidone Iodine in Alcoholic Solutions for Prevention of Central Venous Catheter Infection",[91],"2006-04","2004-05",520,[749],"ICU Patients Requiring a Central Venous Access",[729],{"trials":752,"activeCount":100},[],{"intervention":754,"totalTrials":96,"cells":755},"2%Chlorhexidine-70%Isopropanol",{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":777},{"trials":757,"activeCount":100},[],{"trials":759,"activeCount":100},[],{"trials":761,"activeCount":100},[],{"trials":763,"activeCount":100},[],{"trials":765,"activeCount":100},[766],{"nctId":767,"briefTitle":768,"status":224,"phases":769,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":775},"NCT03560193","Randomized Trial of 2% Chlorhexidine-70% Isopropanol vs 5% Povidone Iodine-69% Ethanol for Skin Antisepsis in Reducing Surgical-site Infection After Cardiac Surgery",[91],"2022-05-25","2018-09-10",3316,[774],"Cardiac Surgery in Adult Patient",[754,776],"5%Povidone Iodine- 69%Ethanol",{"trials":778,"activeCount":100},[],{"intervention":776,"totalTrials":96,"cells":780},{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":789,"NA":795},{"trials":782,"activeCount":100},[],{"trials":784,"activeCount":100},[],{"trials":786,"activeCount":100},[],{"trials":788,"activeCount":100},[],{"trials":790,"activeCount":100},[791],{"nctId":767,"briefTitle":768,"status":224,"phases":792,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":793,"interventions":794},[91],[774],[754,776],{"trials":796,"activeCount":100},[],{"intervention":798,"totalTrials":96,"cells":799},"Aflibercept",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":820},{"trials":801,"activeCount":100},[],{"trials":803,"activeCount":100},[],{"trials":805,"activeCount":100},[],{"trials":807,"activeCount":100},[],{"trials":809,"activeCount":100},[810],{"nctId":811,"briefTitle":812,"status":224,"phases":813,"primaryCompletion":814,"completion":814,"start":815,"enrollment":816,"conditions":817,"interventions":819},"NCT02320474","Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)",[91],"2018-11","2014-11-25",26,[818],"Type 3 Choroidal Neovascularization",[798],{"trials":821,"activeCount":100},[],{"intervention":823,"totalTrials":96,"cells":824},"Imatinib mesylate 100 mg",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":833,"NA":844},{"trials":826,"activeCount":100},[],{"trials":828,"activeCount":100},[],{"trials":830,"activeCount":100},[],{"trials":832,"activeCount":100},[],{"trials":834,"activeCount":100},[835],{"nctId":836,"briefTitle":837,"status":224,"phases":838,"primaryCompletion":839,"start":840,"enrollment":841,"conditions":842,"interventions":843},"NCT00845221","Glivec in Pediatric Chronic Myeloid Leukemia (CML)",[91],"2011-11","2004-07",44,[15],[823],{"trials":845,"activeCount":100},[],{"intervention":847,"totalTrials":171,"cells":848},"Imatinib mesylate 600 mg",{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":866,"PHASE4":880,"NA":882},{"trials":850,"activeCount":100},[],{"trials":852,"activeCount":100},[],{"trials":854,"activeCount":100},[855],{"nctId":856,"briefTitle":857,"status":858,"phases":859,"completion":860,"start":861,"enrollment":515,"conditions":862,"interventions":863},"NCT00219765","Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients","TERMINATED",[88,89],"2006-01","2001-05",[15],[847,864,865],"Cytarabine","Daunorubicine",{"trials":867,"activeCount":100},[868],{"nctId":869,"briefTitle":870,"status":224,"phases":871,"primaryCompletion":872,"completion":872,"start":873,"enrollment":874,"conditions":875,"interventions":876},"NCT00219739","STI571 ProspectIve RandomIzed Trial: SPIRIT",[90],"2014-12","2003-09",789,[15],[877,847,878,879],"Imatinib mesylate 400 mg","Imatinib 400 mg + Peg-Interferon","Imatinib mesylate 400 mg + Cytarabine",{"trials":881,"activeCount":100},[],{"trials":883,"activeCount":100},[],{"intervention":877,"totalTrials":171,"cells":885},{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":890,"PHASE3":900,"PHASE4":906,"NA":908},{"trials":887,"activeCount":100},[],{"trials":889,"activeCount":100},[],{"trials":891,"activeCount":100},[892],{"nctId":893,"briefTitle":894,"status":224,"phases":895,"completion":896,"start":897,"enrollment":515,"conditions":898,"interventions":899},"NCT00219752","Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years",[89],"2007-05","2002-05",[15],[877],{"trials":901,"activeCount":100},[902],{"nctId":869,"briefTitle":870,"status":224,"phases":903,"primaryCompletion":872,"completion":872,"start":873,"enrollment":874,"conditions":904,"interventions":905},[90],[15],[877,847,878,879],{"trials":907,"activeCount":100},[],{"trials":909,"activeCount":100},[],{"intervention":911,"totalTrials":171,"cells":912},"Ciprofloxacin",{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":931,"PHASE3":933,"PHASE4":946,"NA":948},{"trials":914,"activeCount":100},[],{"trials":916,"activeCount":100},[917],{"nctId":918,"briefTitle":919,"status":224,"phases":920,"primaryCompletion":921,"start":922,"enrollment":923,"conditions":924,"interventions":927},"NCT01059890","Cerebral Antibiotics Distribution After Acute Brain Injury",[88],"2013-06","2009-09",18,[925,926],"Bacterial Infection","Brain Injury",[928,929,911,930],"cefotaxime","Metronidazole","Fosfocine",{"trials":932,"activeCount":100},[],{"trials":934,"activeCount":100},[935],{"nctId":936,"briefTitle":937,"status":938,"phases":939,"primaryCompletion":940,"completion":940,"start":941,"enrollment":100,"conditions":942,"interventions":944},"NCT04698057","Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial.","WITHDRAWN",[90],"2025-06-01","2022-03-01",[943],"Febrile Neutropenia",[945,911],"Amoxicillin Clavulanate",{"trials":947,"activeCount":100},[],{"trials":949,"activeCount":100},[],{"intervention":951,"totalTrials":96,"cells":952},"salbutamol",{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":957,"PHASE3":959,"PHASE4":973,"NA":975},{"trials":954,"activeCount":100},[],{"trials":956,"activeCount":100},[],{"trials":958,"activeCount":100},[],{"trials":960,"activeCount":100},[961],{"nctId":962,"briefTitle":963,"status":182,"phases":964,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":972},"NCT03449056","High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease",[90],"2020-01","2020-04","2019-01-11",25,[970,971],"Chronic Obstructive Pulmonary Disease","High-flow Nasal Cannula",[951],{"trials":974,"activeCount":100},[],{"trials":976,"activeCount":100},[],{"intervention":978,"totalTrials":96,"cells":979},"Cyclosporin A: C0: 75-125ng\u002Fml-dose adapted in the 3 groups",{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":1001,"NA":1003},{"trials":981,"activeCount":100},[],{"trials":983,"activeCount":100},[],{"trials":985,"activeCount":100},[],{"trials":987,"activeCount":100},[988],{"nctId":989,"briefTitle":990,"status":224,"phases":991,"completion":992,"start":993,"enrollment":994,"conditions":995,"interventions":997},"NCT00461825","Maintenance Neoral Monotherapy Compared to Bitherapy in Renal Transplantation",[90],"2007-02","1998-07",207,[996],"Kidney Transplantation",[978,998,999,1000],"Group A: CsA + Azathioprine","Group B: CsA + CellCept","Group C: CsAm",{"trials":1002,"activeCount":100},[],{"trials":1004,"activeCount":100},[],{"intervention":998,"totalTrials":96,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1013,"PHASE4":1019,"NA":1021},{"trials":1008,"activeCount":100},[],{"trials":1010,"activeCount":100},[],{"trials":1012,"activeCount":100},[],{"trials":1014,"activeCount":100},[1015],{"nctId":989,"briefTitle":990,"status":224,"phases":1016,"completion":992,"start":993,"enrollment":994,"conditions":1017,"interventions":1018},[90],[996],[978,998,999,1000],{"trials":1020,"activeCount":100},[],{"trials":1022,"activeCount":100},[],{"intervention":999,"totalTrials":96,"cells":1024},{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1031,"PHASE4":1037,"NA":1039},{"trials":1026,"activeCount":100},[],{"trials":1028,"activeCount":100},[],{"trials":1030,"activeCount":100},[],{"trials":1032,"activeCount":100},[1033],{"nctId":989,"briefTitle":990,"status":224,"phases":1034,"completion":992,"start":993,"enrollment":994,"conditions":1035,"interventions":1036},[90],[996],[978,998,999,1000],{"trials":1038,"activeCount":100},[],{"trials":1040,"activeCount":100},[],{"intervention":1000,"totalTrials":96,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1049,"PHASE4":1055,"NA":1057},{"trials":1044,"activeCount":100},[],{"trials":1046,"activeCount":100},[],{"trials":1048,"activeCount":100},[],{"trials":1050,"activeCount":100},[1051],{"nctId":989,"briefTitle":990,"status":224,"phases":1052,"completion":992,"start":993,"enrollment":994,"conditions":1053,"interventions":1054},[90],[996],[978,998,999,1000],{"trials":1056,"activeCount":100},[],{"trials":1058,"activeCount":100},[],{"intervention":1060,"totalTrials":96,"cells":1061},"Daptomycin",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1068,"PHASE4":1081,"NA":1083},{"trials":1063,"activeCount":100},[],{"trials":1065,"activeCount":100},[],{"trials":1067,"activeCount":100},[],{"trials":1069,"activeCount":100},[1070],{"nctId":1071,"briefTitle":1072,"status":224,"phases":1073,"primaryCompletion":1074,"start":1075,"conditions":1076,"interventions":1080},"NCT02142075","Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg\u002Fkg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure",[90],"2015-09","2014-03",[1077,1078,1079],"Renal Failure","Critical Care","Gram Positive Bacteria",[1060],{"trials":1082,"activeCount":100},[],{"trials":1084,"activeCount":100},[],{"intervention":1086,"totalTrials":96,"cells":1087},"Corticoids",{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1094,"PHASE4":1107,"NA":1109},{"trials":1089,"activeCount":100},[],{"trials":1091,"activeCount":100},[],{"trials":1093,"activeCount":100},[],{"trials":1095,"activeCount":100},[1096],{"nctId":1097,"briefTitle":1098,"status":182,"phases":1099,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":1104,"interventions":1106},"NCT03553342","Efficacy of Oral Corticosteroid Therapy in Recurrent Paralyzes After Thyroidectomy",[90],"2021-09-11","2022-01-11","2018-09-11",156,[1105],"Recurrent Paralysis of Vocal Cords",[1086],{"trials":1108,"activeCount":100},[],{"trials":1110,"activeCount":100},[],{"intervention":878,"totalTrials":96,"cells":1112},{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1119,"PHASE4":1125,"NA":1127},{"trials":1114,"activeCount":100},[],{"trials":1116,"activeCount":100},[],{"trials":1118,"activeCount":100},[],{"trials":1120,"activeCount":100},[1121],{"nctId":869,"briefTitle":870,"status":224,"phases":1122,"primaryCompletion":872,"completion":872,"start":873,"enrollment":874,"conditions":1123,"interventions":1124},[90],[15],[877,847,878,879],{"trials":1126,"activeCount":100},[],{"trials":1128,"activeCount":100},[],{"intervention":879,"totalTrials":96,"cells":1130},{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1137,"PHASE4":1143,"NA":1145},{"trials":1132,"activeCount":100},[],{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":100},[],{"trials":1138,"activeCount":100},[1139],{"nctId":869,"briefTitle":870,"status":224,"phases":1140,"primaryCompletion":872,"completion":872,"start":873,"enrollment":874,"conditions":1141,"interventions":1142},[90],[15],[877,847,878,879],{"trials":1144,"activeCount":100},[],{"trials":1146,"activeCount":100},[],{"intervention":945,"totalTrials":96,"cells":1148},{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1155,"PHASE4":1161,"NA":1163},{"trials":1150,"activeCount":100},[],{"trials":1152,"activeCount":100},[],{"trials":1154,"activeCount":100},[],{"trials":1156,"activeCount":100},[1157],{"nctId":936,"briefTitle":937,"status":938,"phases":1158,"primaryCompletion":940,"completion":940,"start":941,"enrollment":100,"conditions":1159,"interventions":1160},[90],[943],[945,911],{"trials":1162,"activeCount":100},[],{"trials":1164,"activeCount":100},[],{"intervention":1166,"totalTrials":96,"cells":1167},"Cisatracurium's monitoring by TOF (train-of-four) WATCH device.",{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1174,"PHASE4":1186,"NA":1188},{"trials":1169,"activeCount":100},[],{"trials":1171,"activeCount":100},[],{"trials":1173,"activeCount":100},[],{"trials":1175,"activeCount":100},[1176],{"nctId":1177,"briefTitle":1178,"status":224,"phases":1179,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":436,"conditions":1182,"interventions":1184},"NCT03198637","Comparison of Neuromuscular Blockade's Monitoring and Clinical Assessment During Cisatracurium Paralysis in Critically Ill Patients",[90],"2018-05","2013-04",[1183],"Critical Illness",[1166,1185],"clinical assessment",{"trials":1187,"activeCount":100},[],{"trials":1189,"activeCount":100},[],{"intervention":1185,"totalTrials":96,"cells":1191},{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1198,"PHASE4":1204,"NA":1206},{"trials":1193,"activeCount":100},[],{"trials":1195,"activeCount":100},[],{"trials":1197,"activeCount":100},[],{"trials":1199,"activeCount":100},[1200],{"nctId":1177,"briefTitle":1178,"status":224,"phases":1201,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":436,"conditions":1202,"interventions":1203},[90],[1183],[1166,1185],{"trials":1205,"activeCount":100},[],{"trials":1207,"activeCount":100},[],{"intervention":1209,"totalTrials":96,"cells":1210},"Anti-Infective Agents",{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1217,"PHASE4":1229,"NA":1231},{"trials":1212,"activeCount":100},[],{"trials":1214,"activeCount":100},[],{"trials":1216,"activeCount":100},[],{"trials":1218,"activeCount":100},[1219],{"nctId":1220,"briefTitle":1221,"status":224,"phases":1222,"primaryCompletion":1223,"completion":1223,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1228},"NCT02265406","PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone",[90],"2020-07-25","2015-10",354,[1227],"Early Ventilation Acquired Pneumonia in Brain Injured Patients",[1209],{"trials":1230,"activeCount":100},[],{"trials":1232,"activeCount":100},[],{"intervention":1234,"totalTrials":96,"cells":1235},"Everolimus",{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1240,"PHASE3":1242,"PHASE4":1257,"NA":1259},{"trials":1237,"activeCount":100},[],{"trials":1239,"activeCount":100},[],{"trials":1241,"activeCount":100},[],{"trials":1243,"activeCount":100},[1244],{"nctId":1245,"briefTitle":1246,"status":224,"phases":1247,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":1251,"conditions":1252,"interventions":1254},"NCT02334488","Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function",[90],"2019-05-31","2020-07-03","2014-12-11",329,[1253],"Chronic Kidney Disease",[1234,1255,1256],"Tacrolimus","Mycophenolate sodium",{"trials":1258,"activeCount":100},[],{"trials":1260,"activeCount":100},[],{"intervention":1255,"totalTrials":96,"cells":1262},{"EARLY_PHASE1":1263,"PHASE1":1265,"PHASE2":1267,"PHASE3":1269,"PHASE4":1275,"NA":1277},{"trials":1264,"activeCount":100},[],{"trials":1266,"activeCount":100},[],{"trials":1268,"activeCount":100},[],{"trials":1270,"activeCount":100},[1271],{"nctId":1245,"briefTitle":1246,"status":224,"phases":1272,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":1251,"conditions":1273,"interventions":1274},[90],[1253],[1234,1255,1256],{"trials":1276,"activeCount":100},[],{"trials":1278,"activeCount":100},[],{"intervention":1256,"totalTrials":96,"cells":1280},{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1287,"PHASE4":1293,"NA":1295},{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":100},[],{"trials":1286,"activeCount":100},[],{"trials":1288,"activeCount":100},[1289],{"nctId":1245,"briefTitle":1246,"status":224,"phases":1290,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":1251,"conditions":1291,"interventions":1292},[90],[1253],[1234,1255,1256],{"trials":1294,"activeCount":100},[],{"trials":1296,"activeCount":100},[],{"intervention":1298,"totalTrials":96,"cells":1299},"Loading bolus of cefoxitin",{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1306,"PHASE4":1323,"NA":1325},{"trials":1301,"activeCount":100},[],{"trials":1303,"activeCount":100},[],{"trials":1305,"activeCount":100},[],{"trials":1307,"activeCount":100},[1308],{"nctId":1309,"briefTitle":1310,"status":182,"phases":1311,"primaryCompletion":44,"completion":1312,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1318},"NCT05755789","Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery",[90],"2025-06","2023-06-22",2000,[1316,1317],"Antibiotic Prophylaxis","Colorectal Surgery",[1298,1319,1320,1321,1322],"Intermittent cefoxitin","Continuous infusion of placebo","Continuous infusion of cefoxitin","Intermittent placebo",{"trials":1324,"activeCount":100},[],{"trials":1326,"activeCount":100},[],{"intervention":1319,"totalTrials":96,"cells":1328},{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1341,"NA":1343},{"trials":1330,"activeCount":100},[],{"trials":1332,"activeCount":100},[],{"trials":1334,"activeCount":100},[],{"trials":1336,"activeCount":100},[1337],{"nctId":1309,"briefTitle":1310,"status":182,"phases":1338,"primaryCompletion":44,"completion":1312,"start":1313,"enrollment":1314,"conditions":1339,"interventions":1340},[90],[1316,1317],[1298,1319,1320,1321,1322],{"trials":1342,"activeCount":100},[],{"trials":1344,"activeCount":100},[],{"intervention":1320,"totalTrials":96,"cells":1346},{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1351,"PHASE3":1353,"PHASE4":1359,"NA":1361},{"trials":1348,"activeCount":100},[],{"trials":1350,"activeCount":100},[],{"trials":1352,"activeCount":100},[],{"trials":1354,"activeCount":100},[1355],{"nctId":1309,"briefTitle":1310,"status":182,"phases":1356,"primaryCompletion":44,"completion":1312,"start":1313,"enrollment":1314,"conditions":1357,"interventions":1358},[90],[1316,1317],[1298,1319,1320,1321,1322],{"trials":1360,"activeCount":100},[],{"trials":1362,"activeCount":100},[],{"intervention":1321,"totalTrials":96,"cells":1364},{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1371,"PHASE4":1377,"NA":1379},{"trials":1366,"activeCount":100},[],{"trials":1368,"activeCount":100},[],{"trials":1370,"activeCount":100},[],{"trials":1372,"activeCount":100},[1373],{"nctId":1309,"briefTitle":1310,"status":182,"phases":1374,"primaryCompletion":44,"completion":1312,"start":1313,"enrollment":1314,"conditions":1375,"interventions":1376},[90],[1316,1317],[1298,1319,1320,1321,1322],{"trials":1378,"activeCount":100},[],{"trials":1380,"activeCount":100},[],{"intervention":1322,"totalTrials":96,"cells":1382},{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1389,"PHASE4":1395,"NA":1397},{"trials":1384,"activeCount":100},[],{"trials":1386,"activeCount":100},[],{"trials":1388,"activeCount":100},[],{"trials":1390,"activeCount":100},[1391],{"nctId":1309,"briefTitle":1310,"status":182,"phases":1392,"primaryCompletion":44,"completion":1312,"start":1313,"enrollment":1314,"conditions":1393,"interventions":1394},[90],[1316,1317],[1298,1319,1320,1321,1322],{"trials":1396,"activeCount":100},[],{"trials":1398,"activeCount":100},[],{"intervention":1400,"totalTrials":96,"cells":1401},"S100B protein dosing",{"EARLY_PHASE1":1402,"PHASE1":1404,"PHASE2":1406,"PHASE3":1408,"PHASE4":1422,"NA":1424},{"trials":1403,"activeCount":100},[],{"trials":1405,"activeCount":100},[],{"trials":1407,"activeCount":100},[],{"trials":1409,"activeCount":100},[1410],{"nctId":1411,"briefTitle":1412,"status":224,"phases":1413,"primaryCompletion":1414,"completion":1415,"start":1416,"enrollment":1417,"conditions":1418,"interventions":1421},"NCT03780062","Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet",[90],"2025-04-28","2025-10-28","2019-01-25",720,[1419,1420],"Minor Traumatic Brain Injury","Treatment by Antiplatelet",[1400],{"trials":1423,"activeCount":100},[],{"trials":1425,"activeCount":100},[],{"intervention":1427,"totalTrials":96,"cells":1428},"nitrous oxide and oxygen",{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1446,"NA":1448},{"trials":1430,"activeCount":100},[],{"trials":1432,"activeCount":100},[],{"trials":1434,"activeCount":100},[],{"trials":1436,"activeCount":100},[1437],{"nctId":1438,"briefTitle":1439,"status":858,"phases":1440,"completion":1441,"start":1442,"enrollment":1443,"conditions":1444,"interventions":1445},"NCT00219713","Evaluation of Pain Intensity During Bone Marrow Biopsy Performed With Inhalation of Pre-Mixed 50 Per Cent Nitrous Oxide and Oxygen Mixture.",[90],"2004-12","2000-03",280,[29],[1427],{"trials":1447,"activeCount":100},[],{"trials":1449,"activeCount":100},[],{"intervention":1451,"totalTrials":96,"cells":1452},"Omexel",{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1457,"PHASE3":1459,"PHASE4":1472,"NA":1474},{"trials":1454,"activeCount":100},[],{"trials":1456,"activeCount":100},[],{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":100},[1461],{"nctId":1462,"briefTitle":1463,"status":224,"phases":1464,"primaryCompletion":1465,"start":1466,"enrollment":1467,"conditions":1468,"interventions":1470},"NCT01061073","Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial",[90],"2012-10","2010-01",73,[1469],"Non-oncological Indication to Ureteral Stenting",[1451,1471],"spasfon",{"trials":1473,"activeCount":100},[],{"trials":1475,"activeCount":100},[],{"intervention":1471,"totalTrials":96,"cells":1477},{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1482,"PHASE3":1484,"PHASE4":1490,"NA":1492},{"trials":1479,"activeCount":100},[],{"trials":1481,"activeCount":100},[],{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[1486],{"nctId":1462,"briefTitle":1463,"status":224,"phases":1487,"primaryCompletion":1465,"start":1466,"enrollment":1467,"conditions":1488,"interventions":1489},[90],[1469],[1451,1471],{"trials":1491,"activeCount":100},[],{"trials":1493,"activeCount":100},[],{"intervention":1495,"totalTrials":96,"cells":1496},"Ciprofloxacine",{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1503,"PHASE4":1516,"NA":1518},{"trials":1498,"activeCount":100},[],{"trials":1500,"activeCount":100},[],{"trials":1502,"activeCount":100},[],{"trials":1504,"activeCount":100},[1505],{"nctId":1506,"briefTitle":1507,"status":858,"phases":1508,"primaryCompletion":1509,"completion":1510,"start":1511,"enrollment":1512,"conditions":1513,"interventions":1515},"NCT00294749","Short or Long Schemes of Antibiotic Prophylaxis for Prostate Biopsy",[90],"2007-12","2008-04","2006-02",300,[1514],"Men Who Must Undergo a Prostate Biopsy Related to Prostate Cancer Suspicion.",[1495],{"trials":1517,"activeCount":100},[],{"trials":1519,"activeCount":100},[],{"intervention":1521,"totalTrials":96,"cells":1522},"Povidone-Iodine",{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1539,"PHASE4":1541,"NA":1543},{"trials":1524,"activeCount":100},[],{"trials":1526,"activeCount":100},[],{"trials":1528,"activeCount":100},[1529],{"nctId":1530,"briefTitle":1531,"status":224,"phases":1532,"primaryCompletion":1533,"completion":1533,"start":1534,"enrollment":1535,"conditions":1536,"interventions":1538},"NCT04371965","Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19",[89],"2020-10-23","2020-09-01",24,[1537],"COVID-19",[1521],{"trials":1540,"activeCount":100},[],{"trials":1542,"activeCount":100},[],{"trials":1544,"activeCount":100},[],{"intervention":1546,"totalTrials":96,"cells":1547},"Duodopa",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1564,"PHASE4":1566,"NA":1568},{"trials":1549,"activeCount":100},[],{"trials":1551,"activeCount":100},[],{"trials":1553,"activeCount":100},[1554],{"nctId":1555,"briefTitle":1556,"status":224,"phases":1557,"primaryCompletion":1558,"start":839,"enrollment":1559,"conditions":1560,"interventions":1562},"NCT01291537","Clinical and Economic Impact of Duodopa: Long-term Effectiveness Study in Advanced Parkinson's Disease Patients",[89],"2016-03",56,[1561],"Parkinson's Disease",[1546,1563],"best médical treatment",{"trials":1565,"activeCount":100},[],{"trials":1567,"activeCount":100},[],{"trials":1569,"activeCount":100},[],{"intervention":1563,"totalTrials":96,"cells":1571},{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1573,"activeCount":100},[],{"trials":1575,"activeCount":100},[],{"trials":1577,"activeCount":100},[1578],{"nctId":1555,"briefTitle":1556,"status":224,"phases":1579,"primaryCompletion":1558,"start":839,"enrollment":1559,"conditions":1580,"interventions":1581},[89],[1561],[1546,1563],{"trials":1583,"activeCount":100},[],{"trials":1585,"activeCount":100},[],{"trials":1587,"activeCount":100},[],{"intervention":1589,"totalTrials":96,"cells":1590},"simvastatin",{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1607,"PHASE4":1609,"NA":1611},{"trials":1592,"activeCount":100},[],{"trials":1594,"activeCount":100},[],{"trials":1596,"activeCount":100},[1597],{"nctId":1598,"briefTitle":1599,"status":224,"phases":1600,"primaryCompletion":1601,"completion":1602,"start":1603,"enrollment":1604,"conditions":1605,"interventions":1606},"NCT02399709","Trial to Evaluate the Efficacy of Simvastatin for Smoking Cessation",[89],"2015-10-08","2017-11-03","2015-04-01",124,[438],[1589],{"trials":1608,"activeCount":100},[],{"trials":1610,"activeCount":100},[],{"trials":1612,"activeCount":100},[],{"intervention":1614,"totalTrials":96,"cells":1615},"cetuximab",{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1632,"PHASE4":1634,"NA":1636},{"trials":1617,"activeCount":100},[],{"trials":1619,"activeCount":100},[],{"trials":1621,"activeCount":100},[1622],{"nctId":1623,"briefTitle":1624,"status":224,"phases":1625,"primaryCompletion":1626,"completion":1626,"start":1627,"enrollment":1628,"conditions":1629,"interventions":1631},"NCT01292356","Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response",[89],"2016-03-03","2010-12-20",28,[1630],"Metastatic Colon Cancer",[1614],{"trials":1633,"activeCount":100},[],{"trials":1635,"activeCount":100},[],{"trials":1637,"activeCount":100},[],{"intervention":1639,"totalTrials":96,"cells":1640},"Gamma Hydroxybutyrate",{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1657,"PHASE4":1659,"NA":1661},{"trials":1642,"activeCount":100},[],{"trials":1644,"activeCount":100},[],{"trials":1646,"activeCount":100},[1647],{"nctId":1648,"briefTitle":1649,"status":224,"phases":1650,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":1653,"conditions":1654,"interventions":1656},"NCT04224246","Impact of Gamma-OH on Sleep in ICU Patients",[89],"2023-02-09","2020-02-27",20,[1655],"Weaning from Mechanical Ventilation",[1639],{"trials":1658,"activeCount":100},[],{"trials":1660,"activeCount":100},[],{"trials":1662,"activeCount":100},[],{"intervention":1664,"totalTrials":96,"cells":1665},"Aflibercept intravitreal injections",{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1670,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1667,"activeCount":100},[],{"trials":1669,"activeCount":100},[],{"trials":1671,"activeCount":100},[1672],{"nctId":1673,"briefTitle":1674,"status":224,"phases":1675,"primaryCompletion":1676,"completion":1677,"start":1678,"enrollment":1679,"conditions":1680,"interventions":1682},"NCT02151695","Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.",[89],"2018-10-31","2020-03-06","2015-05",41,[1681],"Naive Patients With Uncomplicated Proliferative Diabetic Retinopathy",[1664],{"trials":1684,"activeCount":100},[],{"trials":1686,"activeCount":100},[],{"trials":1688,"activeCount":100},[],{"intervention":192,"totalTrials":96,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1695,"PHASE3":1701,"PHASE4":1703,"NA":1705},{"trials":1692,"activeCount":100},[],{"trials":1694,"activeCount":100},[],{"trials":1696,"activeCount":100},[1697],{"nctId":180,"briefTitle":181,"status":182,"phases":1698,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":1699,"interventions":1700},[89],[189,190],[40,192,193,194],{"trials":1702,"activeCount":100},[],{"trials":1704,"activeCount":100},[],{"trials":1706,"activeCount":100},[],{"intervention":193,"totalTrials":96,"cells":1708},{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1713,"PHASE3":1719,"PHASE4":1721,"NA":1723},{"trials":1710,"activeCount":100},[],{"trials":1712,"activeCount":100},[],{"trials":1714,"activeCount":100},[1715],{"nctId":180,"briefTitle":181,"status":182,"phases":1716,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":1717,"interventions":1718},[89],[189,190],[40,192,193,194],{"trials":1720,"activeCount":100},[],{"trials":1722,"activeCount":100},[],{"trials":1724,"activeCount":100},[],{"intervention":1726,"totalTrials":96,"cells":1727},"Lidocaine-Prilocaine 5%",{"EARLY_PHASE1":1728,"PHASE1":1730,"PHASE2":1732,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1729,"activeCount":100},[],{"trials":1731,"activeCount":100},[],{"trials":1733,"activeCount":100},[1734],{"nctId":1735,"briefTitle":1736,"status":224,"phases":1737,"primaryCompletion":1738,"start":1739,"enrollment":1740,"conditions":1741,"interventions":1743},"NCT01673542","Evaluating the Effectiveness of Dermal Analgesia Provided by the Application of Lidocaine and Prilocaine Cream 5% on the Puncture Site of Axillary Blocks",[89],"2013-05","2012-08",32,[1742],"Surgery Scheduled",[1726,1744],"DEXERYL",{"trials":1746,"activeCount":100},[],{"trials":1748,"activeCount":100},[],{"trials":1750,"activeCount":100},[],{"intervention":1744,"totalTrials":96,"cells":1752},{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1763,"PHASE4":1765,"NA":1767},{"trials":1754,"activeCount":100},[],{"trials":1756,"activeCount":100},[],{"trials":1758,"activeCount":100},[1759],{"nctId":1735,"briefTitle":1736,"status":224,"phases":1760,"primaryCompletion":1738,"start":1739,"enrollment":1740,"conditions":1761,"interventions":1762},[89],[1742],[1726,1744],{"trials":1764,"activeCount":100},[],{"trials":1766,"activeCount":100},[],{"trials":1768,"activeCount":100},[],{"intervention":1770,"totalTrials":96,"cells":1771},"idarubicin",{"EARLY_PHASE1":1772,"PHASE1":1774,"PHASE2":1776,"PHASE3":1788,"PHASE4":1790,"NA":1792},{"trials":1773,"activeCount":100},[],{"trials":1775,"activeCount":100},[],{"trials":1777,"activeCount":100},[1778],{"nctId":1779,"briefTitle":1780,"status":224,"phases":1781,"primaryCompletion":1782,"completion":1782,"start":1783,"enrollment":1784,"conditions":1785,"interventions":1787},"NCT01958996","Phase I\u002FII Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma",[88,89],"2016-12-31","2009-01",27,[1786],"High Grade Lymphomas CD20 Positive",[1770],{"trials":1789,"activeCount":100},[],{"trials":1791,"activeCount":100},[],{"trials":1793,"activeCount":100},[],{"intervention":864,"totalTrials":96,"cells":1795},{"EARLY_PHASE1":1796,"PHASE1":1798,"PHASE2":1800,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1797,"activeCount":100},[],{"trials":1799,"activeCount":100},[],{"trials":1801,"activeCount":100},[1802],{"nctId":856,"briefTitle":857,"status":858,"phases":1803,"completion":860,"start":861,"enrollment":515,"conditions":1804,"interventions":1805},[88,89],[15],[847,864,865],{"trials":1807,"activeCount":100},[],{"trials":1809,"activeCount":100},[],{"trials":1811,"activeCount":100},[],{"intervention":865,"totalTrials":96,"cells":1813},{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1818,"PHASE3":1824,"PHASE4":1826,"NA":1828},{"trials":1815,"activeCount":100},[],{"trials":1817,"activeCount":100},[],{"trials":1819,"activeCount":100},[1820],{"nctId":856,"briefTitle":857,"status":858,"phases":1821,"completion":860,"start":861,"enrollment":515,"conditions":1822,"interventions":1823},[88,89],[15],[847,864,865],{"trials":1825,"activeCount":100},[],{"trials":1827,"activeCount":100},[],{"trials":1829,"activeCount":100},[],{"intervention":1831,"totalTrials":96,"cells":1832},"Sugammadex 1 mg\u002Fkg",{"EARLY_PHASE1":1833,"PHASE1":1835,"PHASE2":1837,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1834,"activeCount":100},[],{"trials":1836,"activeCount":100},[],{"trials":1838,"activeCount":100},[1839],{"nctId":1840,"briefTitle":1841,"status":224,"phases":1842,"primaryCompletion":1843,"start":1844,"conditions":1845,"interventions":1847},"NCT02545595","Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients",[89],"2013-12","2012-05",[1846],"Morbid Obesity",[1831,1848,1849],"Sugammadex 2 mg\u002Fkg","Sugammadex 4 mg\u002Fkg",{"trials":1851,"activeCount":100},[],{"trials":1853,"activeCount":100},[],{"trials":1855,"activeCount":100},[],{"intervention":1848,"totalTrials":96,"cells":1857},{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1862,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1859,"activeCount":100},[],{"trials":1861,"activeCount":100},[],{"trials":1863,"activeCount":100},[1864],{"nctId":1840,"briefTitle":1841,"status":224,"phases":1865,"primaryCompletion":1843,"start":1844,"conditions":1866,"interventions":1867},[89],[1846],[1831,1848,1849],{"trials":1869,"activeCount":100},[],{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[],{"intervention":1849,"totalTrials":96,"cells":1875},{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1880,"PHASE3":1886,"PHASE4":1888,"NA":1890},{"trials":1877,"activeCount":100},[],{"trials":1879,"activeCount":100},[],{"trials":1881,"activeCount":100},[1882],{"nctId":1840,"briefTitle":1841,"status":224,"phases":1883,"primaryCompletion":1843,"start":1844,"conditions":1884,"interventions":1885},[89],[1846],[1831,1848,1849],{"trials":1887,"activeCount":100},[],{"trials":1889,"activeCount":100},[],{"trials":1891,"activeCount":100},[],{"intervention":1893,"totalTrials":96,"cells":1894},"mifepristone",{"EARLY_PHASE1":1895,"PHASE1":1897,"PHASE2":1899,"PHASE3":1909,"PHASE4":1911,"NA":1913},{"trials":1896,"activeCount":100},[],{"trials":1898,"activeCount":100},[],{"trials":1900,"activeCount":100},[1901],{"nctId":1902,"briefTitle":1903,"status":858,"phases":1904,"completion":1905,"start":1441,"enrollment":1653,"conditions":1906,"interventions":1908},"NCT00219778","A Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas",[89],"2010-02",[1907],"Leiomyoma",[1893],{"trials":1910,"activeCount":100},[],{"trials":1912,"activeCount":100},[],{"trials":1914,"activeCount":100},[],{"intervention":1916,"totalTrials":96,"cells":1917},"HUMIRA 40mg",{"EARLY_PHASE1":1918,"PHASE1":1920,"PHASE2":1922,"PHASE3":1933,"PHASE4":1935,"NA":1937},{"trials":1919,"activeCount":100},[],{"trials":1921,"activeCount":100},[],{"trials":1923,"activeCount":100},[1924],{"nctId":1925,"briefTitle":1926,"status":224,"phases":1927,"primaryCompletion":1928,"enrollment":1929,"conditions":1930,"interventions":1932},"NCT01872546","Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy",[89],"2013-09",15,[1931],"Chronic Plaque Psoriasis",[1916],{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[],{"trials":1938,"activeCount":100},[],{"intervention":1940,"totalTrials":96,"cells":1941},"hydroxyzine",{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1946,"PHASE3":1959,"PHASE4":1961,"NA":1963},{"trials":1943,"activeCount":100},[],{"trials":1945,"activeCount":100},[],{"trials":1947,"activeCount":100},[1948],{"nctId":1949,"briefTitle":1950,"status":224,"phases":1951,"primaryCompletion":1952,"enrollment":1953,"conditions":1954,"interventions":1956},"NCT01675986","Comparing the Efficacy of Pregabalin and Hydroxyzine on the Anxiety Score",[89],"2014-11",306,[1955],"Feeling Anxious",[1940,1957,1958],"Pregabalin","Lactose",{"trials":1960,"activeCount":100},[],{"trials":1962,"activeCount":100},[],{"trials":1964,"activeCount":100},[],{"intervention":1957,"totalTrials":96,"cells":1966},{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1971,"PHASE3":1977,"PHASE4":1979,"NA":1981},{"trials":1968,"activeCount":100},[],{"trials":1970,"activeCount":100},[],{"trials":1972,"activeCount":100},[1973],{"nctId":1949,"briefTitle":1950,"status":224,"phases":1974,"primaryCompletion":1952,"enrollment":1953,"conditions":1975,"interventions":1976},[89],[1955],[1940,1957,1958],{"trials":1978,"activeCount":100},[],{"trials":1980,"activeCount":100},[],{"trials":1982,"activeCount":100},[],{"intervention":1958,"totalTrials":96,"cells":1984},{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1995,"PHASE4":1997,"NA":1999},{"trials":1986,"activeCount":100},[],{"trials":1988,"activeCount":100},[],{"trials":1990,"activeCount":100},[1991],{"nctId":1949,"briefTitle":1950,"status":224,"phases":1992,"primaryCompletion":1952,"enrollment":1953,"conditions":1993,"interventions":1994},[89],[1955],[1940,1957,1958],{"trials":1996,"activeCount":100},[],{"trials":1998,"activeCount":100},[],{"trials":2000,"activeCount":100},[],{"intervention":2002,"totalTrials":96,"cells":2003},"Liposomal amphotericin B",{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2008,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2005,"activeCount":100},[],{"trials":2007,"activeCount":100},[],{"trials":2009,"activeCount":100},[2010],{"nctId":2011,"briefTitle":2012,"status":224,"phases":2013,"primaryCompletion":2014,"completion":2014,"start":2015,"enrollment":2016,"conditions":2017,"interventions":2019},"NCT02273661","Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).",[89],"2019-06-28","2014-11-19",174,[2018],"Allergic Bronchopulmonary Aspergillosis",[2002],{"trials":2021,"activeCount":100},[],{"trials":2023,"activeCount":100},[],{"trials":2025,"activeCount":100},[],{"intervention":2027,"totalTrials":96,"cells":2028},"Imatinib mesylate",{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2042,"PHASE4":2044,"NA":2046},{"trials":2030,"activeCount":100},[],{"trials":2032,"activeCount":100},[],{"trials":2034,"activeCount":100},[2035],{"nctId":2036,"briefTitle":2037,"status":224,"phases":2038,"completion":2039,"start":897,"enrollment":515,"conditions":2040,"interventions":2041},"NCT00219726","Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation",[89],"2007-07",[15],[2027],{"trials":2043,"activeCount":100},[],{"trials":2045,"activeCount":100},[],{"trials":2047,"activeCount":100},[],{"intervention":2049,"totalTrials":96,"cells":2050},"Dasatinib",{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2066,"PHASE4":2068,"NA":2070},{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":100},[2057],{"nctId":2058,"briefTitle":2059,"status":224,"phases":2060,"primaryCompletion":1676,"completion":1676,"start":2061,"conditions":2062,"interventions":2064},"NCT01872442","Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase",[89],"2013-10-15",[2063],"Chronic Phase of Chronic Myeloid Leukemia",[2049,2065],"Peg-Interferon alpha2b",{"trials":2067,"activeCount":100},[],{"trials":2069,"activeCount":100},[],{"trials":2071,"activeCount":100},[],{"intervention":2065,"totalTrials":96,"cells":2073},{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2078,"PHASE3":2084,"PHASE4":2086,"NA":2088},{"trials":2075,"activeCount":100},[],{"trials":2077,"activeCount":100},[],{"trials":2079,"activeCount":100},[2080],{"nctId":2058,"briefTitle":2059,"status":224,"phases":2081,"primaryCompletion":1676,"completion":1676,"start":2061,"conditions":2082,"interventions":2083},[89],[2063],[2049,2065],{"trials":2085,"activeCount":100},[],{"trials":2087,"activeCount":100},[],{"trials":2089,"activeCount":100},[],{"intervention":2091,"totalTrials":96,"cells":2092},"Atomoxetine",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2094,"activeCount":100},[],{"trials":2096,"activeCount":100},[],{"trials":2098,"activeCount":100},[2099],{"nctId":2100,"briefTitle":2101,"status":858,"phases":2102,"primaryCompletion":2103,"completion":2103,"start":2104,"enrollment":22,"conditions":2105,"interventions":2107},"NCT04354103","Atomoxetine in Patients With Tourette's Syndrome",[89],"2024-01-19","2022-05-31",[2106],"Tourette Syndrome",[2091],{"trials":2109,"activeCount":100},[],{"trials":2111,"activeCount":100},[],{"trials":2113,"activeCount":100},[],{"intervention":2115,"totalTrials":96,"cells":2116},"ranibizumab",{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2133,"PHASE4":2135,"NA":2137},{"trials":2118,"activeCount":100},[],{"trials":2120,"activeCount":100},[],{"trials":2122,"activeCount":100},[2123],{"nctId":2124,"briefTitle":2125,"status":224,"phases":2126,"primaryCompletion":2127,"completion":2127,"start":2128,"enrollment":2129,"conditions":2130,"interventions":2132},"NCT01823965","Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment",[89],"2014-07","2011-10",35,[2131],"Diabetic Macular Edema",[2115],{"trials":2134,"activeCount":100},[],{"trials":2136,"activeCount":100},[],{"trials":2138,"activeCount":100},[],{"intervention":2140,"totalTrials":96,"cells":2141},"Ceftaroline",{"EARLY_PHASE1":2142,"PHASE1":2144,"PHASE2":2156,"PHASE3":2158,"PHASE4":2160,"NA":2162},{"trials":2143,"activeCount":100},[],{"trials":2145,"activeCount":100},[2146],{"nctId":2147,"briefTitle":2148,"status":224,"phases":2149,"primaryCompletion":2150,"completion":2151,"start":2152,"enrollment":923,"conditions":2153,"interventions":2155},"NCT03025841","Population Pharmacokinetic (PK) Study of Zinforo (Ceftaroline) in Critical Care Patients With Early-onset Pneumonia and Normal or Augmented Renal Clearance",[88],"2017-12","2018-06","2016-12",[2154],"Pneumonia",[2140],{"trials":2157,"activeCount":100},[],{"trials":2159,"activeCount":100},[],{"trials":2161,"activeCount":100},[],{"trials":2163,"activeCount":100},[],{"intervention":2165,"totalTrials":96,"cells":2166},"colimycin",{"EARLY_PHASE1":2167,"PHASE1":2169,"PHASE2":2181,"PHASE3":2183,"PHASE4":2185,"NA":2187},{"trials":2168,"activeCount":100},[],{"trials":2170,"activeCount":100},[2171],{"nctId":2172,"briefTitle":2173,"status":224,"phases":2174,"primaryCompletion":2175,"start":2176,"enrollment":2177,"conditions":2178,"interventions":2180},"NCT01060891","Population Pharmacokinetic Study of Colistin in Patients Infected With Multiresistant Gram-negative Bacteria",[88],"2015-04","2009-05",200,[2179],"Gram-negative Bacteria",[2165],{"trials":2182,"activeCount":100},[],{"trials":2184,"activeCount":100},[],{"trials":2186,"activeCount":100},[],{"trials":2188,"activeCount":100},[],{"intervention":2190,"totalTrials":96,"cells":2191},"COLIMYCINE inhalation",{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2205,"PHASE3":2207,"PHASE4":2209,"NA":2211},{"trials":2193,"activeCount":100},[],{"trials":2195,"activeCount":100},[2196],{"nctId":2197,"briefTitle":2198,"status":224,"phases":2199,"primaryCompletion":2200,"start":2128,"enrollment":19,"conditions":2201,"interventions":2203},"NCT01537614","Pharmacokinetic Study of Aerosolized Colimycin in Cystic Fibrosis",[88],"2013-02",[2202],"Cystic Fibrosis",[2190,2204],"COLIMYCINE injectable",{"trials":2206,"activeCount":100},[],{"trials":2208,"activeCount":100},[],{"trials":2210,"activeCount":100},[],{"trials":2212,"activeCount":100},[],{"intervention":2204,"totalTrials":96,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2223,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2216,"activeCount":100},[],{"trials":2218,"activeCount":100},[2219],{"nctId":2197,"briefTitle":2198,"status":224,"phases":2220,"primaryCompletion":2200,"start":2128,"enrollment":19,"conditions":2221,"interventions":2222},[88],[2202],[2190,2204],{"trials":2224,"activeCount":100},[],{"trials":2226,"activeCount":100},[],{"trials":2228,"activeCount":100},[],{"trials":2230,"activeCount":100},[],{"intervention":2232,"totalTrials":96,"cells":2233},"Ertapeneme",{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2245,"PHASE3":2247,"PHASE4":2249,"NA":2251},{"trials":2235,"activeCount":100},[],{"trials":2237,"activeCount":100},[2238],{"nctId":2239,"briefTitle":2240,"status":224,"phases":2241,"conditions":2242,"interventions":2244},"NCT01061047","Comparison of Ertapenem Distribution in the Muscle of Six Healthy Volunteers and Six Critically Ill Patients by Microdialysis",[88],[2243],"Healthy",[2232],{"trials":2246,"activeCount":100},[],{"trials":2248,"activeCount":100},[],{"trials":2250,"activeCount":100},[],{"trials":2252,"activeCount":100},[],{"intervention":2254,"totalTrials":96,"cells":2255},"Paracetamol",{"EARLY_PHASE1":2256,"PHASE1":2258,"PHASE2":2270,"PHASE3":2272,"PHASE4":2274,"NA":2276},{"trials":2257,"activeCount":100},[],{"trials":2259,"activeCount":100},[2260],{"nctId":2261,"briefTitle":2262,"status":224,"phases":2263,"primaryCompletion":2264,"completion":2264,"start":2265,"enrollment":2266,"conditions":2267,"interventions":2269},"NCT03223506","Validation of a Physiological Based Pharmacokinetic Model by the Study of Paracetamol Distribution in the Brain Compartments in Brain Injured Patients",[88],"2017-12-31","2013-03-23",17,[2268],"Brain Injured Patients",[2254],{"trials":2271,"activeCount":100},[],{"trials":2273,"activeCount":100},[],{"trials":2275,"activeCount":100},[],{"trials":2277,"activeCount":100},[],{"intervention":928,"totalTrials":96,"cells":2279},{"EARLY_PHASE1":2280,"PHASE1":2282,"PHASE2":2288,"PHASE3":2290,"PHASE4":2292,"NA":2294},{"trials":2281,"activeCount":100},[],{"trials":2283,"activeCount":100},[2284],{"nctId":918,"briefTitle":919,"status":224,"phases":2285,"primaryCompletion":921,"start":922,"enrollment":923,"conditions":2286,"interventions":2287},[88],[925,926],[928,929,911,930],{"trials":2289,"activeCount":100},[],{"trials":2291,"activeCount":100},[],{"trials":2293,"activeCount":100},[],{"trials":2295,"activeCount":100},[],{"intervention":929,"totalTrials":96,"cells":2297},{"EARLY_PHASE1":2298,"PHASE1":2300,"PHASE2":2306,"PHASE3":2308,"PHASE4":2310,"NA":2312},{"trials":2299,"activeCount":100},[],{"trials":2301,"activeCount":100},[2302],{"nctId":918,"briefTitle":919,"status":224,"phases":2303,"primaryCompletion":921,"start":922,"enrollment":923,"conditions":2304,"interventions":2305},[88],[925,926],[928,929,911,930],{"trials":2307,"activeCount":100},[],{"trials":2309,"activeCount":100},[],{"trials":2311,"activeCount":100},[],{"trials":2313,"activeCount":100},[],{"intervention":930,"totalTrials":96,"cells":2315},{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2324,"PHASE3":2326,"PHASE4":2328,"NA":2330},{"trials":2317,"activeCount":100},[],{"trials":2319,"activeCount":100},[2320],{"nctId":918,"briefTitle":919,"status":224,"phases":2321,"primaryCompletion":921,"start":922,"enrollment":923,"conditions":2322,"interventions":2323},[88],[925,926],[928,929,911,930],{"trials":2325,"activeCount":100},[],{"trials":2327,"activeCount":100},[],{"trials":2329,"activeCount":100},[],{"trials":2331,"activeCount":100},[],{"intervention":2333,"totalTrials":96,"cells":2334},"gentamicin",{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2348,"PHASE3":2350,"PHASE4":2352,"NA":2354},{"trials":2336,"activeCount":100},[],{"trials":2338,"activeCount":100},[2339],{"nctId":2340,"briefTitle":2341,"status":224,"phases":2342,"primaryCompletion":2343,"completion":2344,"start":1224,"enrollment":633,"conditions":2345,"interventions":2347},"NCT02515448","A Pharmacokinetic-pharmacodynamic Dose Comparison Study of 8 mg\u002Fkg of Inhaled or Parenteral Gentamicin in 12 Mechanically Ventilated Critically Ill Patients Treated for Ventilator-associated Pneumonia",[88],"2016-11","2017-01",[2346],"Ventilator-associated Pneumonia",[2333],{"trials":2349,"activeCount":100},[],{"trials":2351,"activeCount":100},[],{"trials":2353,"activeCount":100},[],{"trials":2355,"activeCount":100},[],{"intervention":2357,"totalTrials":96,"cells":2358},"Blodd punction for genetic analysis",{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2365,"PHASE4":2367,"NA":2369},{"trials":2360,"activeCount":100},[],{"trials":2362,"activeCount":100},[],{"trials":2364,"activeCount":100},[],{"trials":2366,"activeCount":100},[],{"trials":2368,"activeCount":100},[],{"trials":2370,"activeCount":100},[2371],{"nctId":2372,"briefTitle":2373,"status":224,"phases":2374,"primaryCompletion":2175,"completion":2375,"start":2376,"enrollment":2377,"conditions":2378,"interventions":2381},"NCT03186144","Clinical and Molecular Study of CHARGE Syndrom",[92],"2015-12","2012-02",141,[2379,2380],"Development Abnormalies","Inclusion on Clinical Criteria of the Syndrome",[2357],{"intervention":2383,"totalTrials":96,"cells":2384},"Control: Analgesia-sedation",{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2389,"PHASE3":2391,"PHASE4":2393,"NA":2395},{"trials":2386,"activeCount":100},[],{"trials":2388,"activeCount":100},[],{"trials":2390,"activeCount":100},[],{"trials":2392,"activeCount":100},[],{"trials":2394,"activeCount":100},[],{"trials":2396,"activeCount":100},[2397],{"nctId":2398,"briefTitle":2399,"status":224,"phases":2400,"primaryCompletion":2401,"completion":2401,"start":2402,"enrollment":541,"conditions":2403,"interventions":2408},"NCT04936880","Pilot Study on the Evaluation of the Effectiveness of a Virtual Reality Device on Anxiety During Procedural Sedation in Traumatology in Emergency Department",[92],"2023-01-18","2021-07-20",[2404,2405,2406,2407],"Reality Device","Reduction Procedure","Fracture","Dislocation",[2383],{"intervention":2410,"totalTrials":96,"cells":2411},"Venetoclax",{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2422},{"trials":2413,"activeCount":100},[],{"trials":2415,"activeCount":100},[],{"trials":2417,"activeCount":100},[],{"trials":2419,"activeCount":100},[],{"trials":2421,"activeCount":100},[],{"trials":2423,"activeCount":100},[2424],{"nctId":2425,"briefTitle":2426,"status":182,"phases":2427,"primaryCompletion":2428,"completion":2429,"start":2428,"enrollment":2430,"conditions":2431,"interventions":2433},"NCT06200220","Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia",[],"2023-12-28","2025-12-01",45,[2432],"Waldenstrom's Macroglobulinaemia Refractory",[2410],{"intervention":2435,"totalTrials":96,"cells":2436},"Amino Acids",{"EARLY_PHASE1":2437,"PHASE1":2439,"PHASE2":2441,"PHASE3":2443,"PHASE4":2445,"NA":2447},{"trials":2438,"activeCount":100},[],{"trials":2440,"activeCount":100},[],{"trials":2442,"activeCount":100},[],{"trials":2444,"activeCount":100},[],{"trials":2446,"activeCount":100},[],{"trials":2448,"activeCount":100},[2449],{"nctId":2450,"briefTitle":2451,"status":224,"phases":2452,"primaryCompletion":2453,"completion":2454,"start":2455,"enrollment":541,"conditions":2456,"interventions":2458},"NCT03644836","Interest of Branched Chain Amino Acids Associated With a Respiratory Rehabilitation Program in Patients Broncho Chronic Obstructive Pulmonary Disease",[92],"2018-01-31","2018-03-05","2015-01-21",[2457],"Broncho Chronic Obstructive Pulmonary Disease",[2435,2459],"Placebos",{"intervention":2459,"totalTrials":96,"cells":2461},{"EARLY_PHASE1":2462,"PHASE1":2464,"PHASE2":2466,"PHASE3":2468,"PHASE4":2470,"NA":2472},{"trials":2463,"activeCount":100},[],{"trials":2465,"activeCount":100},[],{"trials":2467,"activeCount":100},[],{"trials":2469,"activeCount":100},[],{"trials":2471,"activeCount":100},[],{"trials":2473,"activeCount":100},[2474],{"nctId":2450,"briefTitle":2451,"status":224,"phases":2475,"primaryCompletion":2453,"completion":2454,"start":2455,"enrollment":541,"conditions":2476,"interventions":2477},[92],[2457],[2435,2459],{"intervention":2479,"totalTrials":96,"cells":2480},"dabrafenib",{"EARLY_PHASE1":2481,"PHASE1":2483,"PHASE2":2485,"PHASE3":2487,"PHASE4":2489,"NA":2491},{"trials":2482,"activeCount":100},[],{"trials":2484,"activeCount":100},[],{"trials":2486,"activeCount":100},[],{"trials":2488,"activeCount":100},[],{"trials":2490,"activeCount":100},[],{"trials":2492,"activeCount":100},[2493],{"nctId":2494,"briefTitle":2495,"status":224,"phases":2496,"primaryCompletion":2497,"completion":2497,"start":2497,"enrollment":1653,"conditions":2498,"interventions":2500},"NCT03553329","Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK",[],"2018-06-02",[2499],"Unresecable Stage IIIc or IV Melanoma",[2479],{"intervention":440,"totalTrials":96,"cells":2502},{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2507,"PHASE3":2509,"PHASE4":2511,"NA":2513},{"trials":2504,"activeCount":100},[],{"trials":2506,"activeCount":100},[],{"trials":2508,"activeCount":100},[],{"trials":2510,"activeCount":100},[],{"trials":2512,"activeCount":100},[],{"trials":2514,"activeCount":100},[2515],{"nctId":430,"briefTitle":431,"status":182,"phases":2516,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":2517,"interventions":2518},[92],[438],[440,80],{"intervention":2520,"totalTrials":96,"cells":2521},"oxytocin",{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2530,"NA":2532},{"trials":2523,"activeCount":100},[],{"trials":2525,"activeCount":100},[],{"trials":2527,"activeCount":100},[],{"trials":2529,"activeCount":100},[],{"trials":2531,"activeCount":100},[],{"trials":2533,"activeCount":100},[2534],{"nctId":2535,"briefTitle":2536,"status":224,"phases":2537,"primaryCompletion":2538,"start":2539,"enrollment":2540,"conditions":2541,"interventions":2543},"NCT01711060","A Comparison of Balloon Catheter Versus Ocytocin for Cervical Ripening on Scarred Uterus With Unfavorable Cervix",[92],"2014-01","2010-12",204,[2542],"Scarred Uterus",[2520],{"intervention":2545,"totalTrials":96,"cells":2546},"Procedure",{"EARLY_PHASE1":2547,"PHASE1":2549,"PHASE2":2551,"PHASE3":2553,"PHASE4":2555,"NA":2557},{"trials":2548,"activeCount":100},[],{"trials":2550,"activeCount":100},[],{"trials":2552,"activeCount":100},[],{"trials":2554,"activeCount":100},[],{"trials":2556,"activeCount":100},[],{"trials":2558,"activeCount":100},[2559],{"nctId":2560,"briefTitle":2561,"status":182,"phases":2562,"primaryCompletion":2563,"completion":2563,"start":2564,"enrollment":2565,"conditions":2566,"interventions":2571},"NCT04779255","Pain Management During a Photodynamic Therapy Session on the Vertex for Actinic Keratosis: Tumescent Anesthesia Interest",[92],"2022-11","2021-07-28",48,[29,2567,2568,2569,2570],"Actinic Keratosis","Analgesia","Phototerapy","Vertex",[2545,2572],"Control Arm",{"intervention":2572,"totalTrials":96,"cells":2574},{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2579,"PHASE3":2581,"PHASE4":2583,"NA":2585},{"trials":2576,"activeCount":100},[],{"trials":2578,"activeCount":100},[],{"trials":2580,"activeCount":100},[],{"trials":2582,"activeCount":100},[],{"trials":2584,"activeCount":100},[],{"trials":2586,"activeCount":100},[2587],{"nctId":2560,"briefTitle":2561,"status":182,"phases":2588,"primaryCompletion":2563,"completion":2563,"start":2564,"enrollment":2565,"conditions":2589,"interventions":2590},[92],[29,2567,2568,2569,2570],[2545,2572],{"intervention":2592,"totalTrials":96,"cells":2593},"Extended release Tacrolimus-Everolimus association",{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2602,"NA":2604},{"trials":2595,"activeCount":100},[],{"trials":2597,"activeCount":100},[],{"trials":2599,"activeCount":100},[],{"trials":2601,"activeCount":100},[],{"trials":2603,"activeCount":100},[],{"trials":2605,"activeCount":100},[2606],{"nctId":2607,"briefTitle":2608,"status":858,"phases":2609,"primaryCompletion":2610,"completion":2610,"start":2611,"enrollment":2612,"conditions":2613,"interventions":2616},"NCT03228576","Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association",[],"2018-12-18","2017-04-14",16,[2614,2615],"Kidney Transplant","Immunosuppression",[2592],{"intervention":2618,"totalTrials":96,"cells":2619},"Antibiotic",{"EARLY_PHASE1":2620,"PHASE1":2622,"PHASE2":2624,"PHASE3":2626,"PHASE4":2628,"NA":2630},{"trials":2621,"activeCount":100},[],{"trials":2623,"activeCount":100},[],{"trials":2625,"activeCount":100},[],{"trials":2627,"activeCount":100},[],{"trials":2629,"activeCount":100},[],{"trials":2631,"activeCount":100},[2632],{"nctId":2633,"briefTitle":2634,"status":224,"phases":2635,"primaryCompletion":2636,"completion":2636,"start":2637,"enrollment":2638,"conditions":2639,"interventions":2642},"NCT04910698","Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia",[],"2020-06-01","2020-01-01",104,[2640,2641,943],"Bloodstream Infection","Acute Myeloid Leukemia",[2618],{"intervention":2644,"totalTrials":96,"cells":2645},"Immune cells population assesment",{"EARLY_PHASE1":2646,"PHASE1":2648,"PHASE2":2650,"PHASE3":2652,"PHASE4":2654,"NA":2656},{"trials":2647,"activeCount":100},[],{"trials":2649,"activeCount":100},[],{"trials":2651,"activeCount":100},[],{"trials":2653,"activeCount":100},[],{"trials":2655,"activeCount":100},[],{"trials":2657,"activeCount":100},[2658],{"nctId":2659,"briefTitle":2660,"status":224,"phases":2661,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":436,"conditions":2665,"interventions":2667},"NCT03227965","Immunosuppression's Long Term Impact on Anti-tumoral Oversight in Kidney Transplantation",[92],"2018-05-15","2019-02-07","2017-01-13",[2666],"Kidney Transplant; Complications",[2644]]